Lot’s of talk this week about biosimilar legislation as a means of reducing the cost of prescription drugs. It’s actually been an ongoing topic for many years in biotech circles and PBM consulting (www.wbcbaltimore.com). The current expense of biologic drug therapies and the expected growth into chronic disease states for conditions with much higher prevalence makes it major […]